IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Acquires 18,892 Shares of Company Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin bought 18,892 shares of the stock in a transaction that occurred on Wednesday, December 10th. The stock was bought at an average cost of $0.94 per share, for a total transaction of $17,758.48. Following the completion of the purchase, the insider directly owned 885,648 shares of the company’s stock, valued at $832,509.12. This represents a 2.18% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

IRIDEX Price Performance

Shares of IRIDEX stock opened at $0.88 on Thursday. IRIDEX Corporation has a 1 year low of $0.61 and a 1 year high of $1.65. The firm has a market cap of $15.46 million, a PE ratio of -4.40 and a beta of 0.67. The company has a 50 day simple moving average of $0.73 and a two-hundred day simple moving average of $0.95.

IRIDEX (NASDAQ:IRIX) last issued its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The firm had revenue of $12.57 million for the quarter, compared to analysts’ expectations of $13.59 million. As a group, research analysts anticipate that IRIDEX Corporation will post -0.12 earnings per share for the current year.

Institutional Trading of IRIDEX

Several hedge funds and other institutional investors have recently bought and sold shares of the company. United Capital Financial Advisors LLC purchased a new stake in IRIDEX in the second quarter worth approximately $41,000. Weber Capital Management LLC ADV purchased a new position in shares of IRIDEX during the second quarter worth approximately $206,616. Diversify Advisory Services LLC purchased a new position in shares of IRIDEX during the second quarter worth approximately $30,000. Bank of New York Mellon Corp bought a new stake in shares of IRIDEX in the 2nd quarter worth approximately $29,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of IRIDEX by 6.7% in the 1st quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock worth $401,000 after acquiring an additional 25,067 shares during the last quarter. Hedge funds and other institutional investors own 20.10% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, IRIDEX currently has a consensus rating of “Hold” and a consensus price target of $3.00.

Key Stories Impacting IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.